These results, together with data indicating that efficient LV-mediated overexpression of GALC (Fig. 7G) is achievable in hNSC, support the feasibility and therapeutic potential of hNSC gene therapy for the treatment of GLD. This evidence concerns the gene GALC and Krabbe disease.